BACKGROUND: We examined data from a Phase 2 trial {NCT00457821} of ivacaftor, a CFTR potentiator, in cystic fibrosis (CF) patients with aG551D mutation to evaluate standardized approaches to sweat chloride measurement and to explore the use of sweat chloride and nasal potential difference (NPD) to estimate CFTR activity. METHODS: Sweat chloride and NPD were secondary endpoints in this placebo-controlled, multicenter trial. Standardization of sweat collection, processing,and analysis was employed for the first time. Sweat chloride and chloride ion transport (NPD) were integrated into a model of CFTR activity. RESULTS: Within-patient sweat chloride determinations showed sufficient precision to detect differences between dose-groups and assess ivacaftor treatment effects. Analysis of changes in sweat chloride and NPD demonstrated that patients treated with ivacaftor achieved CFTR activity equivalent to approximately 35%–40% of normal. CONCLUSIONS: Sweat chloride is useful in multicenter trials as a biomarker of CFTR activity and to test the effect of CFTR potentiators.
BACKGROUND: We examined data from a Phase 2 trial {NCT00457821} of ivacaftor, a CFTR potentiator, in cystic fibrosis (CF) patients with aG551D mutation to evaluate standardized approaches to sweat chloride measurement and to explore the use of sweat chloride and nasal potential difference (NPD) to estimate CFTR activity. METHODS: Sweat chloride and NPD were secondary endpoints in this placebo-controlled, multicenter trial. Standardization of sweat collection, processing,and analysis was employed for the first time. Sweat chloride and chloride ion transport (NPD) were integrated into a model of CFTR activity. RESULTS: Within-patient sweat chloride determinations showed sufficient precision to detect differences between dose-groups and assess ivacaftor treatment effects. Analysis of changes in sweat chloride and NPD demonstrated that patients treated with ivacaftor achieved CFTR activity equivalent to approximately 35%–40% of normal. CONCLUSIONS: Sweat chloride is useful in multicenter trials as a biomarker of CFTR activity and to test the effect of CFTR potentiators.
Authors: E W Alton; M Stern; R Farley; A Jaffe; S L Chadwick; J Phillips; J Davies; S N Smith; J Browning; M G Davies; M E Hodson; S R Durham; D Li; P K Jeffery; M Scallan; R Balfour; S J Eastman; S H Cheng; A E Smith; D Meeker; D M Geddes Journal: Lancet Date: 1999-03-20 Impact factor: 79.321
Authors: Verena I Seliger; David Rodman; Fredrick Van Goor; Andreas Schmelz; Peter Mueller Journal: J Cyst Fibros Date: 2013-04-28 Impact factor: 5.482
Authors: Bonnie W Ramsey; Jane Davies; N Gerard McElvaney; Elizabeth Tullis; Scott C Bell; Pavel Dřevínek; Matthias Griese; Edward F McKone; Claire E Wainwright; Michael W Konstan; Richard Moss; Felix Ratjen; Isabelle Sermet-Gaudelus; Steven M Rowe; Qunming Dong; Sally Rodriguez; Karl Yen; Claudia Ordoñez; J Stuart Elborn Journal: N Engl J Med Date: 2011-11-03 Impact factor: 91.245
Authors: L C Walker; C J Venglarik; G Aubin; M R Weatherly; N A McCarty; B Lesnick; F Ruiz; J P Clancy; E J Sorscher Journal: Am J Respir Crit Care Med Date: 1997-05 Impact factor: 21.405
Authors: Michele D Bishop; Steven D Freedman; Julian Zielenski; Najma Ahmed; Annie Dupuis; Sheelagh Martin; Lynda Ellis; Julie Shea; Isobel Hopper; Mary Corey; Paul Kortan; Gregory Haber; Christine Ross; John Tzountzouris; Leslie Steele; Peter N Ray; Lap-Chee Tsui; Peter R Durie Journal: Hum Genet Date: 2005-09-29 Impact factor: 4.132
Authors: Fredrick Van Goor; Sabine Hadida; Peter D J Grootenhuis; Bill Burton; Dong Cao; Tim Neuberger; Amanda Turnbull; Ashvani Singh; John Joubran; Anna Hazlewood; Jinglan Zhou; Jason McCartney; Vijayalaksmi Arumugam; Caroline Decker; Jennifer Yang; Chris Young; Eric R Olson; Jeffery J Wine; Raymond A Frizzell; Melissa Ashlock; Paul Negulescu Journal: Proc Natl Acad Sci U S A Date: 2009-10-21 Impact factor: 11.205
Authors: Timothy E Corcoran; Alex S Huber; Michael M Myerburg; Daniel J Weiner; Landon W Locke; Ryan T Lacy; Lawrence Weber; Michael R Czachowski; Darragh J Johnston; Ashok Muthukrishnan; Alison T Lennox; Joseph M Pilewski Journal: J Aerosol Med Pulm Drug Deliv Date: 2019-04-10 Impact factor: 2.849
Authors: Alison E Fohner; Ellen M McDonagh; John P Clancy; Michelle Whirl Carrillo; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2017-01 Impact factor: 2.089
Authors: Ann Chen Wu; James P Kiley; Patricia J Noel; Shashi Amur; Esteban G Burchard; John P Clancy; Joshua Galanter; Maki Inada; Tiffanie K Jones; Jonathan A Kropski; James E Loyd; Lawrence M Nogee; Benjamin A Raby; Angela J Rogers; David A Schwartz; Don D Sin; Avrum Spira; Scott T Weiss; Lisa R Young; Blanca E Himes Journal: Am J Respir Crit Care Med Date: 2018-12-15 Impact factor: 21.405
Authors: Allison F McCague; Karen S Raraigh; Matthew J Pellicore; Emily F Davis-Marcisak; Taylor A Evans; Sangwoo T Han; Zhongzhou Lu; Anya T Joynt; Neeraj Sharma; Carlo Castellani; Joseph M Collaco; Mary Corey; Michelle H Lewis; Chris M Penland; Johanna M Rommens; Anne L Stephenson; Patrick R Sosnay; Garry R Cutting Journal: Am J Respir Crit Care Med Date: 2019-05-01 Impact factor: 21.405
Authors: Meghan E McGarry; Beate Illek; Ngoc P Ly; Lorna Zlock; Sabrina Olshansky; Courtney Moreno; Walter E Finkbeiner; Dennis W Nielson Journal: Pediatr Pulmonol Date: 2017-01-09
Authors: Marianne S Muhlebach; J P Clancy; Sonya L Heltshe; Assem Ziady; Tom Kelley; Frank Accurso; Joseph Pilewski; Nicole Mayer-Hamblett; Elizabeth Joseloff; Scott D Sagel Journal: J Cyst Fibros Date: 2016-10-27 Impact factor: 5.482
Authors: Jennifer Guimbellot; George M Solomon; Arthur Baines; Sonya L Heltshe; Jill VanDalfsen; Elizabeth Joseloff; Scott D Sagel; Steven M Rowe Journal: J Cyst Fibros Date: 2018-04-21 Impact factor: 5.482
Authors: George M Solomon; Inez Bronsveld; Kathryn Hayes; Michael Wilschanski; Paola Melotti; Steven M Rowe; Isabelle Sermet-Gaudelus Journal: J Vis Exp Date: 2018-09-13 Impact factor: 1.355